At the news
? BULLISHIMPACT 7/10 8-K filed Aug 4, 2026 at 07:02 ET
Pfizer reported Q2 2026 adjusted EPS of $0.77 (12.9% beat vs $0.68 consensus) and revenue of $15.0B (4.5% beat vs $14.4B consensus), raised full-year 2026 revenue guidance by $500M midpoint to $60.5-$62.5B, and reaffirmed adjusted EPS guidance of $2.80-$3.00 despite absorbing a ~$0.10 impact from the Innovent biologics transaction. Strength in non-COVID products (Eliquis +19%, Padcev +23%, Lorbrena +37%) drove 18% operational growth in launched/acquired products, offsetting COVID revenue declines, while GAAP reported a net loss of $0.04 per share due to $4.3B in non-cash intangible asset impairments.
- Adjusted diluted EPS of $0.77 beat consensus of $0.68 by 13.2%
- Revenue of $15.034B rose 3% YoY (1% operational); ex-COVID, revenue grew 5% operationally
- Full-year 2026 revenue guidance raised $500M at midpoint to $60.5-$62.5B; adjusted EPS guidance reaffirmed at $2.80-$3.00
- GAAP reported a loss of $(0.04)/share due to $4.3B in non-cash intangible asset impairments (sigvotatug vedotin $3.8B, Oxbryta $525M)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access